Skip to content
10-Q

Quarterly Report

BIOCANCELL THERAPEUTICS INC.

0001178913-12-001404

← back to feed
Filed
May 10, 2012 12:00 AM ET
Period of report
—

On SEC.gov

Filing index ↗

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2012 · May 9, 2012 39.39M sh
Shares Diluted Q1 2012 · Mar 31, 2012 36.03M sh
Shares Diluted Q1 2012 · Mar 31, 2012 16.29M sh
Shares Diluted Q1 2012 · Mar 31, 2011 26.39M sh
Stock Repurchased Q1 2012 · Mar 31, 2012 $4.95M
Capex Q1 2012 · Mar 31, 2012 $237K
Capex Q1 2012 · Mar 31, 2011 $5K
Operating Cash Flow Q1 2012 · Mar 31, 2012 −$1.53M
Operating Cash Flow Q1 2012 · Mar 31, 2012 −$24.69M
Operating Cash Flow Q1 2012 · Mar 31, 2011 −$590K
Cash And Equivalents Q1 2012 · Mar 31, 2012 $1.59M
Cash And Equivalents Q1 2012 · Dec 31, 2011 $240K
Cash And Equivalents Q1 2012 · Mar 31, 2011 $2.89M
Cash And Equivalents Q1 2012 · Dec 31, 2010 $3.49M
Stockholders Equity Q1 2012 · Mar 31, 2012 −$661K
Stockholders Equity Q1 2012 · Dec 31, 2011 −$3.5M
Current Liabilities Q1 2012 · Mar 31, 2012 $3.02M
Current Liabilities Q1 2012 · Dec 31, 2011 $3.99M
Current Assets Q1 2012 · Mar 31, 2012 $2.63M
Current Assets Q1 2012 · Dec 31, 2011 $808K
Total Assets Q1 2012 · Mar 31, 2012 $3M
Total Assets Q1 2012 · Dec 31, 2011 $1.4M
Eps Diluted Q1 2012 · Mar 31, 2012 −$0.07
Eps Diluted Q1 2012 · Mar 31, 2012 −$1.81
Eps Diluted Q1 2012 · Mar 31, 2011 −$0.07
Eps Basic Q1 2012 · Mar 31, 2012 −$0.07
Eps Basic Q1 2012 · Mar 31, 2012 −$1.90
Eps Basic Q1 2012 · Mar 31, 2011 −$0.07
Sga Expense Q1 2012 · Mar 31, 2012 $449K
Sga Expense Q1 2012 · Mar 31, 2012 $10.83M
Sga Expense Q1 2012 · Mar 31, 2011 $512K
Rd Expense Q1 2012 · Mar 31, 2012 $923K
Rd Expense Q1 2012 · Mar 31, 2012 $18.33M
Rd Expense Q1 2012 · Mar 31, 2011 $690K
Net Income Q1 2012 · Mar 31, 2012 −$2.39M
Net Income Q1 2012 · Mar 31, 2012 −$27.71M
Net Income Q1 2012 · Mar 31, 2011 −$1.78M
Operating Income Q1 2012 · Mar 31, 2012 −$1.2M
Operating Income Q1 2012 · Mar 31, 2012 −$26.16M
Operating Income Q1 2012 · Mar 31, 2011 −$1.14M